Future target-based drug discovery for tuberculosis?

Tuberculosis

Volumn 94, Issue 6, 2014, Pages 551-556

  Kana, Bavesh Davandra ^a   Karakousis, Petros C ^b,c   Parish, Tanya ^d   Dick, Thomas ^e  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^e NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Drug development; Drug targets; Target vulnerability; Tuberculosis; Whole cell screens

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; BEDAQUILINE; CLOFAZIMINE; DELAMANID; LINEZOLID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PRETOMANID; PYRAZINAMIDE; RIFAPENTINE; STRUCTURAL PROTEIN; THIOPHENE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CELL METABOLISM; DNA REPAIR; DRUG DESIGN; DRUG IDENTIFICATION; DRUG PENETRATION; DRUG RESISTANT TUBERCULOSIS; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; GROWTH INHIBITION; HUMAN; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; TUBERCULOSIS; DRUG DEVELOPMENT; DRUG EFFECTS; MOLECULARLY TARGETED THERAPY; PROCEDURES; TRENDS;

ANTITUBERCULAR AGENTS; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84919443395     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2014.10.003     Document Type: Review

References (56)

1. A. Zumla, A. George, V. Sharma, N. Herbert, and Baroness Masham of I WHO's 2013 global report on tuberculosis: successes, threats, and opportunities Lancet 382 2013 1765 1767
2. A. Zumla, M. Raviglione, R. Hafner, and C.F. von Reyn Tuberculosis N Engl J Med 368 2013 745 755
3. A. Zumla, P. Nahid, and S.T. Cole Advances in the development of new tuberculosis drugs and treatment regimens Nat Rev Drug Discov 12 2013 388 404
4. I. Abubakar, M. Zignol, D. Falzon, M. Raviglione, L. Ditiu, S. Masham, I. Adetifa, N. Ford, H. Cox, S.D. Lawn, B.J. Marais, T.D. McHugh, P. Mwaba, M. Bates, M. Lipman, L. Zijenah, S. Logan, R. McNerney, A. Zumla, K. Sarda, P. Nahid, M. Hoelscher, M. Pletschette, Z.A. Memish, P. Kim, R. Hafner, S. Cole, G.B. Migliori, M. Maeurer, and M. Schito Drug-resistant tuberculosis: time for visionary political leadership Lancet Infect Dis 13 2013 529 539
5. A. Zumla, R. Hafner, C. Lienhardt, M. Hoelscher, and A. Nunn Advancing the development of tuberculosis therapy Nat Rev Drug Discov 11 2012 171 172
6. A. Zumla, P. Kim, M. Maeurer, and M. Schito Zero deaths from tuberculosis: progress, reality, and hope Lancet Infect Dis 13 2013 285 287
7. R.S. Wallis Sustainable tuberculosis drug development Clin Infect Dis 56 2013 106 113
8. A. Zumla, M. Rao, S.K. Parida, S. Keshavjee, G. Cassell, R. Wallis, R. Axelsson-Robertsson, M. Doherty, J. Andersson, and M. Maeurer Inflammation and tuberculosis: host-directed therapies J Intern Med 2014 [in press]
9. A. Zumla, and M. Maeurer Rational development of adjunct immune-based therapies for drug-resistant tuberculosis: hypotheses and experimental designs J Infect Dis 205 Suppl. 2 2012 S335 S339
10. D.J. Payne, M.N. Gwynn, D.J. Holmes, and D.L. Pompliano Drugs for bad bugs: confronting the challenges of antibacterial discovery Nat Rev Drug Discov 6 2007 29 40
11. J.C. Palomino, and A. Martin TMC207 becomes bedaquiline, a new anti-TB drug Future Microbiol 8 2013 1071 1080
12. A.H. Diacon, R. Dawson, F. Von Groote-Bidlingmaier, G. Symons, A. Venter, P.R. Donald, A. Conradie, N. Erondu, A.M. Ginsberg, E. Egizi, H. Winter, P. Becker, and C.M. Mendel Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis Antimicrob Agents Chemother 57 2013 2199 2203
13. A.H. Diacon, A. Pym, M. Grobusch, R. Patientia, R. Rustomjee, L. Page-Shipp, C. Pistorius, R. Krause, M. Bogoshi, G. Churchyard, A. Venter, J. Allen, J.C. Palomino, T. De Marez, R.P. van Heeswijk, N. Lounis, P. Meyvisch, J. Verbeeck, W. Parys, K. de Beule, K. Andries, and D.F. Mc Neeley The diarylquinoline TMC207 for multidrug-resistant tuberculosis N Engl J Med 360 2009 2397 2405
14. S. Esposito, L. D'Ambrosio, M. Tadolini, H.S. Schaaf, J. Caminero Luna, B. Marais, R. Centis, M. Dara, A. Matteelli, F. Blasi, and G.B. Migliori ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use Eur Respir J 44 2014 811 815
15. V. Skripconoka, M. Danilovits, L. Pehme, T. Tomson, G. Skenders, T. Kummik, A. Cirule, V. Leimane, A. Kurve, K. Levina, L.J. Geiter, D. Manissero, and C.D. Wells Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis Eur Respir J 41 2012 1393 1400
16. M.T. Gler, V. Skripconoka, E. Sanchez-Garavito, H. Xiao, J.L. Cabrera-Rivero, D.E. Vargas-Vasquez, M. Gao, M. Awad, S.K. Park, T.S. Shim, G.Y. Suh, M. Danilovits, H. Ogata, A. Kurve, J. Chang, K. Suzuki, T. Tupasi, W.J. Koh, B. Seaworth, L.J. Geiter, and C.D. Wells Delamanid for multidrug-resistant pulmonary tuberculosis N Engl J Med 366 2012 2151 2160
17. A.H. Diacon, R. Dawson, M. Hanekom, K. Narunsky, A. Venter, N. Hittel, L.J. Geiter, C.D. Wells, A.J. Paccaly, and P.R. Donald Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients Int J Tuberc Lung Dis 15 2011 949 954
18. R. Dawson, and A. Diacon PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis Expert Opin Investig Drugs 22 2013 927 932
19. A.H. Diacon, R. Dawson, F. von Groote-Bidlingmaier, G. Symons, A. Venter, P.R. Donald, C. van Niekerk, D. Everitt, H. Winter, P. Becker, C.M. Mendel, and M.K. Spigelman 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial Lancet 380 2012 986 993
20. A.H. Diacon, R. Dawson, J. du Bois, K. Narunsky, A. Venter, P.R. Donald, C. van Niekerk, N. Erondu, A.M. Ginsberg, P. Becker, and M.K. Spigelman Phase II dose-ranging trial of the early bactericidal activity of PA-824 Antimicrob Agents Chemother 56 2012 3027 3031
21. U. Manjunatha, H.I. Boshoff, and C.E. Barry The mechanism of action of PA-824: novel insights from transcriptional profiling Commun Integr Biol 2 2009 215 218
22. R. Singh, U. Manjunatha, H.I. Boshoff, Y.H. Ha, P. Niyomrattanakit, R. Ledwidge, C.S. Dowd, I.Y. Lee, P. Kim, L. Zhang, S. Kang, T.H. Keller, J. Jiricek, and C.E. Barry III PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release Science 322 2008 1392 1395
23. C. Trefzer, M. Rengifo-Gonzalez, M.J. Hinner, P. Schneider, V. Makarov, S.T. Cole, and K. Johnsson Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-beta-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis J Am Chem Soc 132 2010 13663 13665
24. V. Makarov, G. Manina, K. Mikusova, U. Mollmann, O. Ryabova, B. Saint-Joanis, N. Dhar, M.R. Pasca, S. Buroni, A.P. Lucarelli, A. Milano, E. De Rossi, M. Belanova, A. Bobovska, P. Dianiskova, J. Kordulakova, C. Sala, E. Fullam, P. Schneider, J.D. McKinney, P. Brodin, T. Christophe, S. Waddell, P. Butcher, J. Albrethsen, I. Rosenkrands, R. Brosch, V. Nandi, S. Bharath, S. Gaonkar, R.K. Shandil, V. Balasubramanian, T. Balganesh, S. Tyagi, J. Grosset, G. Riccardi, and S.T. Cole Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis Science 324 2009 801 804
25. S. Kang, R.Y. Kim, M.J. Seo, S. Lee, Y.M. Kim, M. Seo, J.J. Seo, Y. Ko, I. Choi, J. Jang, J. Nam, S. Park, H. Kang, H.J. Kim, J. Kim, S. Ahn, K. Pethe, K. Nam, and Z. No Lead optimization of a novel series of imidazo[1,2-a]pyridine amides Leading to a clinical candidate (Q203) as a multi- and extensively-drug resistant antituberculosis agent J Med Chem 57 2014 5293 5305
26. K. Pethe, P. Bifani, J. Jang, S. Kang, S. Park, S. Ahn, J. Jiricek, J. Jung, H.K. Jeon, J. Cechetto, T. Christophe, H. Lee, M. Kempf, M. Jackson, A.J. Lenaerts, H. Pham, V. Jones, M.J. Seo, Y.M. Kim, M. Seo, J.J. Seo, D. Park, Y. Ko, I. Choi, R. Kim, S.Y. Kim, S. Lim, S.A. Yim, J. Nam, H. Kang, H. Kwon, C.T. Oh, Y. Cho, Y. Jang, J. Kim, A. Chua, B.H. Tan, M.B. Nanjundappa, S.P. Rao, W.S. Barnes, R. Wintjens, J.R. Walker, S. Alonso, S. Lee, S. Oh, T. Oh, U. Nehrbass, S.J. Han, Z. No, J. Lee, P. Brodin, S.N. Cho, and K. Nam Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis Nat Med 19 2013 1157 1160
27. G.C. Moraski, L.D. Markley, J. Cramer, P.A. Hipskind, H. Boshoff, M. Bailey, T. Alling, J. Ollinger, T. Parish, and M.J. Miller Advancement of Imidazo[1,2-a]pyridines with improved pharmacokinetics and nanomolar activity against Mycobacterium tuberculosis ACS Med Chem Lett 4 2013 675 679
28. K.A. Abrahams, J.A. Cox, V.L. Spivey, N.J. Loman, M.J. Pallen, C. Constantinidou, R. Fernandez, C. Alemparte, M.J. Remuinan, D. Barros, L. Ballell, and G.S. Besra Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB PLoS One 7 2012 e52951
29. K. Li, L.A. Schurig-Briccio, X. Feng, A. Upadhyay, V. Pujari, B. Lechartier, F.L. Fontes, H. Yang, G. Rao, W. Zhu, A. Gulati, J.H. No, G. Cintra, S. Bogue, Y.L. Liu, K. Molohon, P. Orlean, D.A. Mitchell, L. Freitas-Junior, F. Ren, H. Sun, T. Jiang, Y. Li, R.T. Guo, S.T. Cole, R.B. Gennis, D.C. Crick, and E. Oldfield Multitarget drug discovery for tuberculosis and other infectious diseases J Med Chem 57 2014 3126 3139
30. M. Lee, J. Lee, M.W. Carroll, H. Choi, S. Min, T. Song, L.E. Via, L.C. Goldfeder, E. Kang, B. Jin, H. Park, H. Kwak, H. Kim, H.S. Jeon, I. Jeong, J.S. Joh, R.Y. Chen, K.N. Olivier, P.A. Shaw, D. Follmann, S.D. Song, J.K. Lee, D. Lee, C.T. Kim, V. Dartois, S.K. Park, S.N. Cho, and C.E. Barry III Linezolid for treatment of chronic extensively drug-resistant tuberculosis N Engl J Med 367 2012 1508 1518
31. K.N. Williams, S.J. Brickner, C.K. Stover, T. Zhu, A. Ogden, R. Tasneen, S. Tyagi, J.H. Grosset, and E.L. Nuermberger Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis Am J Respir Crit Care Med 180 2009 371 376
32. K.N. Williams, C.K. Stover, T. Zhu, R. Tasneen, S. Tyagi, J.H. Grosset, and E. Nuermberger Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model Antimicrob Agents Chemother 53 2009 1314 1319
33. V. Balasubramanian, S. Solapure, H. Iyer, A. Ghosh, S. Sharma, P. Kaur, R. Deepthi, V. Subbulakshmi, V. Ramya, V. Ramachandran, M. Balganesh, L. Wright, D. Melnick, S.L. Butler, and V.K. Sambandamurthy Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis Antimicrob Agents Chemother 58 2014 495 502
34. T. Dey, G. Brigden, H. Cox, Z. Shubber, G. Cooke, and N. Ford Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis J Antimicrob Chemother 68 2012 284 293
35. T. Yano, S. Kassovska-Bratinova, J.S. Teh, J. Winkler, K. Sullivan, A. Isaacs, N.M. Schechter, and H. Rubin Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species J Biol Chem 286 2011 10276 10287
36. R.J. Harbeck, G.S. Worthen, T.D. Lebo, and C.A. Peloquin Clofazimine crystals in the cytoplasm of pulmonary macrophages Ann Pharmacother 33 1999 250
37. D. Zhang, Y. Lu, K. Liu, B. Liu, J. Wang, G. Zhang, H. Zhang, Y. Liu, B. Wang, M. Zheng, L. Fu, Y. Hou, N. Gong, Y. Lv, C. Li, C.B. Cooper, A.M. Upton, D. Yin, Z. Ma, and H. Huang Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis J Med Chem 55 2012 8409 8417
38. J.H. Haapanen, I. Kass, G. Gensini, and G. Middlebrook Studies on the gaseous content of tuberculous cavities Am Rev Respir Dis 80 1959 1 5
39. R.O. Loebel, E. Shorr, and H.B. Richardson The influence of Foodstuffs upon the respiratory metabolism and growth of human tubercle bacilli J Bacteriol 26 1933 139 166
40. J.E. Gomes, and J.D. McKinney Persistence and drug tolerance W.N. Rom, S.M. Garay, Tuberculosis 2004 Lippincott Williams & Wilkins Philadelphia 101 114
41. J.R. Wei, V. Krishnamoorthy, K. Murphy, J.H. Kim, D. Schnappinger, T. Alber, C.M. Sassetti, K.Y. Rhee, and E.J. Rubin Depletion of antibiotic targets has widely varying effects on growth Proc Natl Acad Sci U S A 108 2011 4176 4181
42. T. Dick, and D. Young How antibacterials really work: impact on drug discovery Future Microbiol 6 2011 603 604
43. H.I. Boshoff, M.B. Reed, C.E. Barry 3rd, and V. Mizrahi DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis cell 113 2003 183 193
44. D.F. Warner, D.E. Ndwandwe, G.L. Abrahams, B.D. Kana, E.E. Machowski, C. Venclovas, and V. Mizrahi Essential roles for imuA'- and imuB-encoded accessory factors in DnaE2-dependent mutagenesis in Mycobacterium tuberculosis Proc Natl Acad Sci U S A 107 2010 13093 13098
45. N.K. Dutta, and P.C. Karakousis Latent tuberculosis infection: myths, models, and molecular mechanisms Microbiol Mol Biol Rev 78 2014 343 371
46. H. Esmail, C.E. Barry 3rd, D.B. Young, and R.J. Wilkinson The ongoing challenge of latent tuberculosis Philos Trans R Soc Lond B Biol Sci 369 2014 20130437
47. H.I. Boshoff, and C.E. Barry Is the mycobacterial cell wall a hopeless drug target for latent tuberculosis Drug Discov Today Dis Mech 3 2006 237 245
48. Z. Xu, W. Yin, L.K. Martinelli, J. Evans, J. Chen, Y. Yu, D.J. Wilson, V. Mizrahi, C. Qiao, and C.C. Aldrich Reaction intermediate analogues as bisubstrate inhibitors of pantothenate synthetase Bioorg Med Chem 22 2014 1726 1735
49. A. Kumar, A. Casey, J. Odingo, E.A. Kesicki, G. Abrahams, M. Vieth, T. Masquelin, V. Mizrahi, P.A. Hipskind, D.R. Sherman, and T. Parish A high-throughput screen against pantothenate synthetase (PanC) identifies 3-biphenyl-4-cyanopyrrole-2-carboxylic acids as a new class of inhibitor with activity against Mycobacterium tuberculosis PLoS One 8 2013 e72786
50. G.L. Abrahams, A. Kumar, S. Savvi, A.W. Hung, S. Wen, C. Abell, C.E. Barry 3rd, D.R. Sherman, H.I. Boshoff, and V. Mizrahi Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening Chem Biol 19 2012 844 854
51. R. Wilson, P. Kumar, V. Parashar, C. Vilcheze, R. Veyron-Churlet, J.S. Freundlich, S.W. Barnes, J.R. Walker, M.J. Szymonifka, E. Marchiano, S. Shenai, R. Colangeli, W.R. Jacobs Jr., M.B. Neiditch, L. Kremer, and D. Alland Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis Nat Chem Biol 9 2013 499 506
52. D.M. O'Sullivan, J. Hinds, P.D. Butcher, S.H. Gillespie, and T.D. McHugh Mycobacterium tuberculosis DNA repair in response to subinhibitory concentrations of ciprofloxacin J Antimicrob Chemother 62 2008 1199 1202
53. L.R. Mesak, V. Miao, and J. Davies Effects of subinhibitory concentrations of antibiotics on SOS and DNA repair gene expression in Staphylococcus aureus Antimicrob Agents Chemother 52 2008 3394 3397
54. B. Faller, and L. Urban Hit and lead profiling: identification and optimization of drug-like molecules R. Mannhold, H. Kubinyi, G. Folkers, Methods and principles in medicinal chemistry 2009 Wiley-VCH Weinheim
55. J. Bowes, A.J. Brown, J. Hamon, W. Jarolimek, A. Sridhar, G. Waldron, and S. Whitebread Reducing safety-related drug attrition: the use of in vitro pharmacological profiling Nat Rev Drug Discov 11 2012 909 922
56. B. Lechartier, J. Rybniker, A. Zumla, and S.T. Cole Tuberculosis drug discovery in the post-post-genomic era EMBO Mol Med 6 2014 158 168